Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.The US Food and Drug Administration (FDA) has granted fast track designation to RLF-100 (Aviptadil), which is being developed by NeuroRx and Relief Therapeutics to treat acute lung injury / acute respiratory distress syndrome caused by Covid-19.
RLF-100 is a synthetic version of human Vasoactive Intestinal Peptide (VIP), which decreases inflammation in the lungs. It is also known to protect the alveolar type II cells that act as an entry route for the SARS-CoV-2 into the lungs.